Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer.

H Ozen1

  • 1Hacettepe University, Ankara, Turkey.

Current Opinion in Oncology
|June 1, 1992
PubMed
Summary
This summary is machine-generated.

Researchers are investigating novel tumor markers for bladder cancer, including oncogenes and growth factor receptors. Bacillus Calmette-Guerrin immunotherapy shows promise for superficial bladder cancer, but optimal use and neoadjuvant chemotherapy require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new adjacent tool in the management of clinical T1a solid renal masses.

Actas urologicas espanolas·2026
Same author

Neutrophil volume distribution width as a new marker in detecting inflammatory bowel disease activation.

International journal of laboratory hematology·2016
Same author

Successful outcome with second hematopoietic stem cell transplantation in a patient with IL-10R deficiency.

Bone marrow transplantation·2015
Same author

Is routine stenting necessary in pyeloplasty?

Pediatric surgery international·2013
Same author

Can p53, Ki-67 and bcl-2 predict biochemical failure after radical prostatectomy?

Indian journal of urology : IJU : journal of the Urological Society of India·2010
Same author

Pathological, biochemical and haematological investigations on the protective effect of alpha-lipoic acid in experimental aflatoxin toxicosis in chicks.

British poultry science·2010
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Urology
  • Immunotherapy

Background:

  • Bladder carcinoma diagnosis and treatment require sensitive and specific markers.
  • Oncogenes (e.g., c-erb B-2, p53) and epidermal growth factor receptor are under investigation as potential bladder cancer biomarkers.
  • Bacillus Calmette-Guerrin (BCG) is a key immunotherapy for superficial bladder cancer.

Purpose of the Study:

  • To review the current status of tumor markers for bladder carcinoma.
  • To discuss the efficacy and knowledge gaps in Bacillus Calmette-Guerrin immunotherapy for superficial bladder cancer.
  • To evaluate the role of neoadjuvant chemotherapy in invasive bladder cancer.

Main Methods:

  • Literature review of oncogene and growth factor receptor expression in bladder cancer.

Related Experiment Videos

  • Analysis of current data on Bacillus Calmette-Guerrin (BCG) treatment efficacy and mechanisms.
  • Assessment of neoadjuvant chemotherapy studies in invasive bladder cancer.

    • Main Results:

    • Expression of oncogenes and growth factor receptors shows potential as predictive markers, though results are not yet conclusive.
    • Bacillus Calmette-Guerrin (BCG) immunotherapy is effective in superficial bladder cancer, but optimal protocols and mechanisms require further research.
    • Neoadjuvant chemotherapy shows promise for invasive bladder cancer, but requires validation through large-scale, randomized controlled trials.

    Conclusions:

    • Emerging tumor markers may improve bladder cancer detection and prediction.
    • Further research is needed to optimize Bacillus Calmette-Guerrin (BCG) immunotherapy for bladder cancer.
    • Evidence for neoadjuvant chemotherapy in invasive bladder cancer warrants cautious interpretation pending survival data from robust clinical trials.